SCHEMBL615315

SCHEMBL615315

Cc1c(Cl)cccc1S(=O)(=O)Nc1ccc2[nH]c(=O)sc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.58
ALDH1A1 P00352 2/20 0.54
PKM P14618 2/20 0.54
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54
BRD4 O60885 1/20 0.48
GSPT1 P15170 1/20 0.46
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.46
THRB P10828 1/20 0.46
HPGD P15428 1/20 0.46
HSD11B1 P28845 2/20 0.45
SLC40A1 Q9NP59 1/20 0.44
EDNRB P24530 1/20 0.44
EDNRA P25101 1/20 0.44
KIF11 P52732 1/20 0.43
PGR P06401 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL618067 0.83 BRD4 (0.56) PKMMAPTBRD4GSPT1DDB1
SCHEMBL616758 0.79 HSD11B1 (0.53) PKMBRD4GSPT1DDB1CRBN
SCHEMBL617881 0.77 LMNA (0.62) TP53ALDH1A1PKMPOLBMAPT
SCHEMBL617123 0.77 LMNA (0.62) ALDH1A1PKMMAPTMEN1KMT2A
SCHEMBL616421 0.77 HSD11B1 (0.51) ALDH1A1PKMBRD4GSPT1DDB1
SCHEMBL615849 0.76 IDH1 (0.52) PKMBRD4GSPT1DDB1CRBN
SCHEMBL614858 0.75 LMNA (0.60) ALDH1A1PKMMAPTMEN1KMT2A
SCHEMBL5347991 0.74 MEN1 (0.78) ALDH1A1PKMPOLBMAPTMEN1
SCHEMBL10089752 0.74 PKM (0.68) TP53ALDH1A1PKMPOLBMEN1
SCHEMBL614790 0.74 PKM (0.56) TP53ALDH1A1PKMPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20120041207-A1 Compound STERIX LIMITED (GB) 2012-02-16 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-20110009448-A1 Compound STERIX LIMITED 2011-01-13 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-7786152-B2 Compound STERIX LIMITED (GB) 2010-08-31 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer STERIX LIMITED (GB) 2008-05-15 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
US-7309715-B2 Compound STERIX LIMITED (GB) 2007-12-18 US disclosed
EP-1556040-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 Sterix Limited (GB) 2005-07-27 EP disclosed
US-20040143124-A1 Compound STERIX LIMITED (GB) 2004-07-22 US disclosed
WO-2004037251-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2 STERIX LIMITED (GB) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114042-A1 Inhibiting 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD); use of sulfonamide-substituted N-heterocyclics including pyrroles, oxazoles, thiazoles, imidazoles and their fused analogs to treat diabetes, obesity, hypertension, arthritis, asthma, osteoporosis, breast cancer HSD11B1, HSD3B1, HSD11B2 TP53 2714/4885ALDH1A1 236/4885PKM 2539/4885
US-20110009448-A1 Compound NR4A1, GPR6, PRMT6 TP53 3850/4885ALDH1A1 1319/4885PKM 3481/4885
US-20120041207-A1 Compound NR4A1, GPR6, PRMT6 TP53 3850/4885ALDH1A1 1319/4885PKM 3481/4885
US-20040143124-A1 Compound NR4A1, CBR1, NR2C2 TP53 4119/4885ALDH1A1 553/4885PKM 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.